Abstract
GENERAL COMMENTARY article Front. Neurol., 29 September 2014Sec. Neuropharmacology https://doi.org/10.3389/fneur.2014.00182
Highlights
In their article, Franco and CedazoMinguez open the debate on why it is difficult to translate successful preclinical research in Alzheimer’s disease (AD) mouse models into clinical practice [1]
Many of the therapies assayed on the AD models that are ineffective in people with the already established pathology might possibly be effective in preventing or delaying disease progression toward dementia
None of the animal models may represent the best option for evaluating novel therapeutic approaches for mild to moderate AD cases, they might be the first step in evaluating drugs that could reverse the synapse loss that underlies the “silent” phase of the disease
Summary
Franco and CedazoMinguez open the debate on why it is difficult to translate successful preclinical research in Alzheimer’s disease (AD) mouse models into clinical practice [1]. Despite a full preclinical and clinical trial package, the large majority of drugs with initial phases based on translational-laboratory-based discoveries fail to complete the development process.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
